Abstract
The defective generation or function of regulatory T (Treg) cells in autoimmune disease contributes to chronic inflammation and tissue injury. We report the identification of FoxA1 as a transcription factor in T cells that, after ectopic expression, confers suppressive properties in a newly identified Treg cell population, herein called FoxA1+ Treg cells. FoxA1 bound to the Pdl1 promoter, inducing programmed cell death ligand 1 (Pd-l1) expression, which was essential for the FoxA1+ Treg cells to kill activated T cells. FoxA1+ Treg cells develop primarily in the central nervous system in response to autoimmune inflammation, have a distinct transcriptional profile and are CD4+FoxA1+CD47+CD69+PD-L1hiFoxP3−. Adoptive transfer of stable FoxA1+ Treg cells inhibited experimental autoimmune encephalomyelitis in a FoxA1–and Pd-l1–dependent manner. The development of FoxA1+ Treg cells is induced by interferon-β (IFN-β) and requires T cell–intrinsic IFN-α/β receptor (Ifnar) signaling, as the frequency of FoxA1+ Treg cells was reduced in Ifnb−/− and Ifnar−/− mice. In individuals with relapsing-remitting multiple sclerosis, clinical response to treatment with IFN-β was associated with an increased frequency of suppressive FoxA1+ Treg cells in the blood. These findings suggest that FoxA1 is a lineage-specification factor that is induced by IFN-β and supports the differentiation and suppressive function of FoxA1+ Treg cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Josefowicz, S.Z., Lu, L.F. & Rudensky, A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012).
Sundrud, M.S. & Nolan, M.A. Synergistic and combinatorial control of T cell activation and differentiation by transcription factors. Curr. Opin. Immunol. 22, 286–292 (2010).
Yamane, H. & Paul, W.E. Early signaling events that underlie fate decisions of naive CD4+ T cells toward distinct T-helper cell subsets. Immunol. Rev. 252, 12–23 (2013).
Bach, J.F. Autoimmune diseases as the loss of active “self-control”. Ann. NY Acad. Sci. 998, 161–177 (2003).
Himmel, M.E., Yao, Y., Orban, P.C., Steiner, T.S. & Levings, M.K. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology 136, 115–122 (2012).
Kumar, V., Stellrecht, K. & Sercarz, E. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J. Exp. Med. 184, 1609–1617 (1996).
Liu, Y., Teige, I., Birnir, B. & Issazadeh-Navikas, S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat. Med. 12, 518–525 (2006).
Korn, T. et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13, 423–431 (2007).
Viglietta, V., Baecher-Allan, C., Weiner, H.L. & Hafler, D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971–979 (2004).
Dominguez-Villar, M., Baecher-Allan, C.M. & Hafler, D.A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 17, 673–675 (2011).
Astier, A.L., Meiffren, G., Freeman, S. & Hafler, D.A. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 116, 3252–3257 (2006).
de Andrés, C. et al. Interferon β-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 182, 204–211 (2007).
Teige, I. et al. IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170, 4776–4784 (2003).
Prinz, M. et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28, 675–686 (2008).
Liu, Y., Teige, I., Ericsson, I., Navikas, V. & Issazadeh-Navikas, S. Suppression of EAE by oral tolerance is independent of endogenous IFN-β whereas treatment with recombinant IFN-β ameliorates EAE. Immunol. Cell Biol. 88, 468–476 (2010).
Teige, I., Liu, Y. & Issazadeh-Navikas, S. IFN-β inhibits T cell activation capacity of central nervous system APCs. J. Immunol. 177, 3542–3553 (2006).
Hurtado, A., Holmes, K.A., Ross-Innes, C.S., Schmidt, D. & Carroll, J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27–33 (2011).
Taube, J.H., Allton, K., Duncan, S.A., Shen, L. & Barton, M.C. Foxa1 functions as a pioneer transcription factor at transposable elements to activate Afp during differentiation of embryonic stem cells. J. Biol. Chem. 285, 16135–16144 (2010).
Laganière, J. et al. Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. USA 102, 11651–11656 (2005).
Li, Z. et al. Foxa1 and Foxa2 regulate bile duct development in mice. J. Clin. Invest. 119, 1537–1545 (2009).
Motallebipour, M. et al. Differential binding and co-binding pattern of FOXA1 and FOXA3 and their relation to H3K4me3 in HepG2 cells revealed by ChIP-seq. Genome Biol. 10, R129 (2009).
Kaestner, K.H. The FoxA factors in organogenesis and differentiation. Curr. Opin. Genet. Dev. 20, 527–532 (2010).
Bernardo, G.M. & Keri, R.A. FOXA1: a transcription factor with parallel functions in development and cancer. Biosci. Rep. 32, 113–130 (2012).
Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958–970 (2008).
Lucchinetti, C.F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188–2197 (2011).
Freeman, G.J., Wherry, E.J., Ahmed, R. & Sharpe, A.H. Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade. J. Exp. Med. 203, 2223–2227 (2006).
Liu, Y. et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci. 33, 14231–14245 (2013).
Hill, J.A. et al. Foxp3 transcription-factor–dependent and –independent regulation of the regulatory T cell transcriptional signature. Immunity 27, 786–800 (2007).
Samstein, R.M. et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 151, 153–166 (2012).
Fu, W. et al. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat. Immunol. 13, 972–980 (2012).
Haribhai, D. et al. A central role for induced regulatory T cells in tolerance induction in experimental colitis. J. Immunol. 182, 3461–3468 (2009).
Wherry, E.J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670–684 (2007).
Jain, J. et al. Normal peripheral T-cell function in c-Fos–deficient mice. Mol. Cell Biol. 14, 1566–1574 (1994).
André, S., Tough, D.F., Lacroix-Desmazes, S., Kaveri, S.V. & Bayry, J. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am. J. Pathol. 174, 1575–1587 (2009).
Porrini, A.M., De Luca, G., Gambi, D. & Reder, A.T. Effects of an anti–IL-10 monoclonal antibody on rIFNβ-1b–mediated immune modulation. Relevance to multiple sclerosis. J. Neuroimmunol. 81, 109–115 (1998).
Zhang, X. et al. IFN-β1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J. Immunol. 182, 3928–3936 (2009).
Hesse, D. et al. Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis? Eur. J. Neurol. 18, 266–272 (2011).
Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001).
Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H. & Freeman, G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122 (2007).
Ono, K. & Han, J. The p38 signal transduction pathway: activation and function. Cell Signal. 12, 1–13 (2000).
Qian, X., Samadani, U., Porcella, A. & Costa, R.H. Decreased expression of hepatocyte nuclear factor 3α during the acute-phase response influences transthyretin gene transcription. Mol. Cell. Biol. 15, 1364–1376 (1995).
Río, J. et al. Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59, 344–352 (2006).
Izcue, A., Coombes, J.L. & Powrie, F. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27, 313–338 (2009).
Kondo, A. et al. Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes. Blood 116, 1124–1131 (2010).
Latchman, Y.E. et al. PD-L1–deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101, 10691–10696 (2004).
Sandner, S.E. et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 174, 3408–3415 (2005).
Keir, M.E. et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883–895 (2006).
Francisco, L.M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029 (2009).
Collison, L.W. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566–569 (2007).
Collison, L.W. et al. IL-35–mediated induction of a potent regulatory T cell population. Nat. Immunol. 11, 1093–1101 (2010).
Jozwik, K.M. & Carroll, J.S. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 12, 381–385 (2012).
Nakshatri, H. & Badve, S. FOXA1 in breast cancer. Expert Rev. Mol. Med. 11, e8 (2009).
Wölfle, S.J. et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol. 41, 413–424 (2011).
Frank, S.R., Schroeder, M., Fernandez, P., Taubert, S. & Amati, B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 15, 2069–2082 (2001).
Carlsson, R., Thorell, K., Liberg, D. & Leanderson, T. SPI-C and STAT6 can cooperate to stimulate IgE germline transcription. Biochem. Biophys. Res. Commun. 344, 1155–1160 (2006).
Lublin, F.D. & Reingold, S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46, 907–911 (1996).
Acknowledgements
This work was supported by grants from The Lundbeck Foundation in Denmark, The Danish Multiple Sclerosis Society, The Danish Council for Independent Research–Medical Sciences, The Danish Cancer Society, The Swedish Research Council–Medicine and the Bibi and Nils Jensen Foundation to S.I.-N. We thank H. Wekerle, U. Grohmann and M. Prinz for valuable discussion and suggestions.
Author information
Authors and Affiliations
Contributions
Y.L. performed experiments, analyzed and prepared data for presentation and contributed to the writing of the manuscript. R.C. performed experiments and analyzed data and contributed to the writing of the manuscript. J.W., M.K., B.C., M.H. and X.W. performed experiments. M.K., B.C., M.H., X.W., M.C., X.M., M.H.D., F.S. and P.S.S. contributed to collection of patients' blood and clinical studies. K.H. contributed to discussions and final revision of the manuscript. S.I.-N. planned the study design, supervised the overall project, analyzed data and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The University of Copenhagen holds the rights to a submitted patent application in which S.I.-N., Y.L. and R.C. are the co-inventors.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–11, Supplementary Tables 1–11 and Supplementary Methods (PDF 3306 kb)
Rights and permissions
About this article
Cite this article
Liu, Y., Carlsson, R., Comabella, M. et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med 20, 272–282 (2014). https://doi.org/10.1038/nm.3485
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3485
This article is cited by
-
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice
Cell Communication and Signaling (2023)
-
Effects of high-fat diet on thyroid autoimmunity in the female rat
BMC Endocrine Disorders (2022)
-
FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A
Oncogene (2022)
-
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
Nature Communications (2022)
-
Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
Scientific Reports (2021)